NZ509348A - Use of a somatostatin analogue Lanreotide - Google Patents

Use of a somatostatin analogue Lanreotide

Info

Publication number
NZ509348A
NZ509348A NZ509348A NZ50934899A NZ509348A NZ 509348 A NZ509348 A NZ 509348A NZ 509348 A NZ509348 A NZ 509348A NZ 50934899 A NZ50934899 A NZ 50934899A NZ 509348 A NZ509348 A NZ 509348A
Authority
NZ
New Zealand
Prior art keywords
lanreotide
somatostatin analogue
cys
pancreatic
psuedocysts
Prior art date
Application number
NZ509348A
Inventor
Jacques-Pierre Moreau
Original Assignee
Sod Conseils Rech Applic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sod Conseils Rech Applic filed Critical Sod Conseils Rech Applic
Publication of NZ509348A publication Critical patent/NZ509348A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/31Somatostatins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12Antidiarrhoeals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/12Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/02Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/06Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A61P5/08Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/18Drugs for disorders of the endocrine system of the parathyroid hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/02Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Zoology (AREA)
  • Vascular Medicine (AREA)
  • Nutrition Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A use in the manufacture of a medicament of the compound H-â-D-Nal-Cys-Try-D-Trp-Lys-Val-Cys-Thr-NH2 -, to treat a disease condition selected from pancreatic psuedocysts, pancreatic ascites, nesidoblastosis, Zollinger- Ellison Syndrome, diabetic neuropathy, small bowel obstruction, cancer cachexia and other conditions.
NZ509348A 1998-07-30 1999-07-29 Use of a somatostatin analogue Lanreotide NZ509348A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9469398P 1998-07-30 1998-07-30
US12652598A 1998-07-30 1998-07-30
PCT/US1999/017294 WO2000006185A2 (en) 1998-07-30 1999-07-29 Methods of using lanreotide, a somatostatin analogue

Publications (1)

Publication Number Publication Date
NZ509348A true NZ509348A (en) 2004-02-27

Family

ID=26789150

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ509348A NZ509348A (en) 1998-07-30 1999-07-29 Use of a somatostatin analogue Lanreotide

Country Status (16)

Country Link
EP (1) EP1100532A2 (en)
JP (1) JP2002521456A (en)
KR (1) KR20010071071A (en)
CN (1) CN1334742A (en)
AR (1) AR023633A1 (en)
AU (2) AU770193B2 (en)
BR (1) BR9912609A (en)
CA (1) CA2335654A1 (en)
CZ (1) CZ2001157A3 (en)
HU (1) HUP0102839A3 (en)
IL (2) IL140837A0 (en)
MX (1) MXPA01000969A (en)
NO (1) NO324123B1 (en)
NZ (1) NZ509348A (en)
PL (1) PL346361A1 (en)
WO (1) WO2000006185A2 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1040837A3 (en) * 1999-02-26 2002-01-02 Erasmus Universiteit Rotterdam Medicaments for the treatment of a choroidal neovascularization (CNV) related disorder
AU2001283957A1 (en) * 2000-07-27 2002-02-13 Novartis Ag Treatment of ocular disorders with somatostatin analogues
US6316414B1 (en) 2000-07-31 2001-11-13 Dabur Research Foundation Somatostatin analogs for the treatment of cancer
ATE430162T1 (en) 2001-03-06 2009-05-15 Il Consorzio Ferrara Richerche METHOD FOR MODULATING THYROID CANCER CELL PROLIFERATION
GB0109461D0 (en) * 2001-04-18 2001-06-06 Univ London New Gene
AU2003216084A1 (en) 2002-01-22 2003-09-02 New York University Methods for therapeutic treatment of benign prostatic hypertrophy (bph)
US20110171191A1 (en) 2008-06-12 2011-07-14 Syntaxin Limited Suppression of neuroendocrine diseases
US10240138B2 (en) 2008-06-12 2019-03-26 Ipsen Bioinnovation Limited Polypeptides that bind to and inhibit secretion from growth hormone secreting cells
GB0820970D0 (en) 2008-11-17 2008-12-24 Syntaxin Ltd Suppression of cancer
CN101935252B (en) * 2010-07-29 2013-01-30 广东省农业科学院科技情报研究所 Landscape plant growth retardant and preparation method thereof
MX362533B (en) * 2012-04-12 2019-01-23 Novartis Ag Combination of somatostatin-analogs with 11beta-hydroxylase inhibitors.
CN105168115A (en) * 2015-09-02 2015-12-23 中国药科大学 Oral medication path of somatostatin analogue polypeptide drug
WO2017212390A1 (en) * 2016-06-06 2017-12-14 Emcure Pharmaceuticals Ltd, Process for lanreotide acetate preparation

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4853371A (en) * 1986-06-17 1989-08-01 The Administrators Of The Tulane Educational Fund Therapeutic somatostatin analogs
US5538739A (en) * 1989-07-07 1996-07-23 Sandoz Ltd. Sustained release formulations of water soluble peptides
CA2046594A1 (en) * 1989-12-08 1991-06-09 David H. Coy Octapeptide analogs of somatostatin having threonine at the sixth position
WO1998008528A1 (en) * 1996-08-30 1998-03-05 Biomeasure Incorporated Method of inhibiting fibrosis with a somatostatin agonist
AU4133997A (en) * 1996-09-12 1998-04-02 Yarom Cohen Pharmaceutical composition for the treatment of syndrome x of reaven
ES2216290T3 (en) * 1997-05-13 2004-10-16 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. SOMATOSTATIN AND AGOMISTS OF SOMATOSTATIN FOR THE TREATMENT OF INSENSITIVITY TO INSULIN AND SYNDROME X.

Also Published As

Publication number Publication date
JP2002521456A (en) 2002-07-16
HUP0102839A2 (en) 2002-01-28
AR023633A1 (en) 2002-09-04
NO20010481D0 (en) 2001-01-29
CA2335654A1 (en) 2000-02-10
AU770193B2 (en) 2004-02-12
IL181349A0 (en) 2007-07-04
AU5244799A (en) 2000-02-21
MXPA01000969A (en) 2003-04-07
AU2004201783A1 (en) 2004-05-27
WO2000006185A3 (en) 2000-08-03
PL346361A1 (en) 2002-02-11
KR20010071071A (en) 2001-07-28
CN1334742A (en) 2002-02-06
HUP0102839A3 (en) 2002-02-28
CZ2001157A3 (en) 2002-02-13
WO2000006185A2 (en) 2000-02-10
IL140837A0 (en) 2002-02-10
NO20010481L (en) 2001-03-21
BR9912609A (en) 2001-05-02
EP1100532A2 (en) 2001-05-23
NO324123B1 (en) 2007-08-27

Similar Documents

Publication Publication Date Title
NZ509348A (en) Use of a somatostatin analogue Lanreotide
DK1112275T3 (en) Novel heteroaromatic inhibitors of fructose-1,6-bisphosphatase
CY1107829T1 (en) NEW UNION EXTERNAL RACERS
MXPA02008722A (en) Novel aryl fructose 1,6 bisphosphatase inhibitors.
ES2297902T5 (en) Novel agonist compounds from exendina
NO20015607L (en) Glukagonantagonister / inversagonister
HK1026229A1 (en) Modified dorsal tissue affecting factor and compositions
BR0314153B1 (en) "Method of preparing a tobacco material with low levels of lignin and nitrogen compounds".
WO2001047935A3 (en) Novel bisamidate phosphonate prodrugs
NO20004589L (en) Spray-tested, degradable ball seal for feeding pipe perforations
MXPA04002751A (en) Modification of feeding behavior.
GB0213612D0 (en) Organic compounds
DK1265971T3 (en) Bioadhesive composition comprising a polyphenol protein
CY1109695T1 (en) Oxalate degradation microorganisms or oxalate degradation enzyme for the prevention of oxalate-related disease
ZA200100607B (en) Methods of treating diabetic cardiomyopathy using glycogen phosphorylase inhibitors.
NZ516349A (en) Conjugates of phytosterol or phytostanol with ascorbic acid and use thereof in treating or preventing cardiovascular disease
ZA200006733B (en) Compositions comprising organic mono- or dinitrate for treating impotence.
FI981506A (en) Elastomer composition and process for its preparation
MXPA00007394A (en) Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases.
ZA200109345B (en) Method of enhancing insulin action.
AU2180501A (en) Novel DNA polymerase inhibitors, mikanolide and dihydromikanolide
SE0100684D0 (en) New subject matter
HUP0101514A2 (en) Composition for and treatment of inflammatory bowel disease by colon administration of n-acetylglucosamine
BR0009208B1 (en) compositions containing grafted polycarbonate and rubber having improved hardness at low temperature.
WO1999053064A3 (en) Methods of delivering glp-1

Legal Events

Date Code Title Description
ASS Change of ownership

Owner name: SOCIETE DE CONSEILS DE RECHERCHES ET D APPLICA, FR

Free format text: OLD OWNER(S): BIOMEASURE, INCORPORATED

Owner name: SOCIETE DE CONSEILS DE RECHERCHES ET D APPLICA, FR

Free format text: OLD OWNER(S): SOCIETE DE CONSEILS DE RECHERCHES ET D APPLICATIONS SCIENTIFIQUES, S.A.; JACQUES-PIERRE MOREAU

PSEA Patent sealed
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)